Cytarabine is a Intrathecal; Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Hospira, Inc.. The primary component is Cytarabine.
Product ID | 61703-305_2f1e0d27-db5b-4e1c-bc4e-956da5dd7117 |
NDC | 61703-305 |
Product Type | Human Prescription Drug |
Proprietary Name | Cytarabine |
Generic Name | Cytarabine |
Dosage Form | Injection, Solution |
Route of Administration | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
Marketing Start Date | 1990-06-04 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA071868 |
Labeler Name | Hospira, Inc. |
Substance Name | CYTARABINE |
Active Ingredient Strength | 20 mg/mL |
Pharm Classes | Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 1990-06-04 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA071868 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2018-06-19 |
Marketing Category | ANDA |
Application Number | ANDA071868 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 1990-06-04 |
Ingredient | Strength |
---|---|
CYTARABINE | 20 mg/mL |
SPL SET ID: | bc2fa221-ea56-48b8-8304-42cd81b8463b |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
61703-303 | CYTARABINE | CYTARABINE |
61703-304 | Cytarabine | CYTARABINE |
61703-305 | Cytarabine | CYTARABINE |
61703-319 | Cytarabine | CYTARABINE |
63323-120 | Cytarabine | CYTARABINE |
67457-452 | Cytarabine | Cytarabine |
67457-454 | Cytarabine | Cytarabine |
67457-455 | cytarabine | cytarabine |
68083-337 | Cytarabine | Cytarabine |
68083-343 | Cytarabine | Cytarabine |
71288-108 | Cytarabine | Cytarabine |
71288-109 | Cytarabine | Cytarabine |
71288-168 | Cytarabine | Cytarabine |
71288-169 | Cytarabine | Cytarabine |